RiceBran Technologies (RIBT) 10-Q 12 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 28, 2020
Cover [Abstract]
Entity Registrant Name	RiceBran Technologies
Entity Central Index Key	0001063537
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		40,207,398
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Address, State or Province	TX

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Condensed Consolidated Statements of Operations (Unaudited) [Abstract]
Revenues	$ 5,903	$ 6,219	$ 14,233	$ 12,583
Cost of goods sold	7,127	6,463	15,862	12,484
Gross profit (loss)	(1,224)	(244)	(1,629)	99
Selling, general and administrative expenses	2,615	3,422	5,165	6,763
Operating loss	(3,839)	(3,666)	(6,794)	(6,664)
Other income (expense):
Interest income	8	23	19	23
Interest expense	(76)	(19)	(125)	(31)
Other expense	(42)	(3)	(87)	(4)
Other income	0	6	5	6
Total other income (expense), net	(110)	7	(188)	(6)
Loss before income taxes	(3,949)	(3,659)	(6,982)	(6,670)
Income tax benefit	0	0	0	0
Loss from continuing operations	(3,949)	(3,659)	(6,982)	(6,670)
Loss from discontinued operations	0	0	0	(216)
Net loss	$ (3,949)	$ (3,659)	$ (6,982)	$ (6,886)
Basic loss per common share:
Continuing operations (in dollars per share)	$ (0.10)	$ (0.11)	$ (0.17)	$ (0.21)
Discontinued operations (in dollars per share)	0	0	0	(0.01)
Basic loss per common share (in dollars per share)	(0.10)	(0.11)	(0.17)	(0.22)
Diluted loss per common share:
Continuing operations (in dollars per share)	(0.10)	(0.11)	(0.17)	(0.21)
Discontinued operations (in dollars per share)	0	0	0	(0.01)
Diluted loss per common share (in dollars per share)	$ (0.10)	$ (0.11)	$ (0.17)	$ (0.22)
Weighted average number of shares outstanding:
Basic (in shares)	40,052,163	33,204,332	40,007,660	31,382,927
Diluted (in shares)	40,052,163	33,204,332	40,007,660	31,382,927

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) [Abstract]
Net loss	$ (3,949)	$ (3,659)	$ (6,982)	$ (6,886)
Derivative financial instruments designated as cash flow hedges:
Losses arising during the period	(100)	0	(100)	0
Reclassification of losses realized to cost of goods sold	52	0	52	0
Net other comprehensive loss	(48)	0	(48)	0
Comprehensive loss	$ (3,997)	$ (3,659)	$ (7,030)	$ (6,886)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 3,347	$ 8,444
Accounts receivable, net of allowance for doubtful accounts of $24 and $347	2,718	3,738
Inventories	2,009	898
Other current assets	1,392	691
Total current assets	9,466	13,771
Property and equipment, net	18,523	19,077
Operating lease right-of-use assets	2,604	2,752
Goodwill	3,915	3,915
Intangible assets	833	950
Other long-term assets	0	27
Total assets	35,341	40,492
Current liabilities:
Accounts payable	949	833
Commodities payable	198	829
Accrued salary, wages and benefits	1,051	877
Accrued expenses	473	884
Customer prepayments	0	12
Operating lease liabilities, current portion	325	309
Due under insurance premium finance agreements	307	116
Due under factoring agreement	2,053	1,823
Finance lease liabilities, current portion	96	101
Long-term debt, current portion	29	28
Total current liabilities	5,481	5,812
Operating lease liabilities, less current portion	2,474	2,674
Finance lease liabilities, less current portion	150	190
Long-term debt, less current portion	1,847	73
Total liabilities	9,952	8,749
Commitments and contingencies
Shareholders' equity:
Common stock, no par value, 150,000,000 shares authorized, 40,207,398 shares and 40,074,483 shares, issued and outstanding	319,487	318,811
Accumulated deficit	(294,162)	(287,180)
Accumulated other comprehensive loss	(48)	0
Total shareholders' equity	25,389	31,743
Total liabilities and shareholders' equity	35,341	40,492
Series G Convertible Preferred Stock [Member]
Shareholders' equity:
Preferred stock, 20,000,000 shares authorized: Series G, convertible, 3,000 shares authorized, stated value $225, 225 shares, issued and outstanding	$ 112	$ 112

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Accounts receivable, allowance for doubtful accounts	$ 24	$ 347
Shareholders' equity:
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	40,207,398	40,074,483
Common stock, shares outstanding (in shares)	40,207,398	40,074,483
Series G Convertible Preferred Stock [Member]
Shareholders' equity:
Preferred stock, shares authorized (in shares)	3,000	3,000
Preferred stock, stated value	$ 225	$ 225
Convertible preferred stock, shares issued (in shares)	225	225
Convertible preferred stock, shares outstanding (in shares)	225	225

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flow from operating activities:
Net loss	$ (6,982)	$ (6,886)
Loss from discontinued operations	0	216
Loss from continuing operations	(6,982)	(6,670)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:
Depreciation	1,157	853
Amortization	117	20
Stock and share-based compensation	664	643
Loss on disposition of property and equipment	308	0
Other	(107)	(2)
Changes in operating assets and liabilities, net of impact of acquisitions:
Accounts receivable	1,090	(774)
Inventories	(1,111)	(5)
Accounts payable and accrued expenses	(201)	(348)
Commodities payable	(631)	(768)
Other	(675)	(398)
Net cash used in operating activities	(6,371)	(7,449)
Cash flows from investing activities:
Purchases of property and equipment	(843)	(2,319)
Acquisition of MGI	0	(3,795)
Net cash used in investing activities	(843)	(6,114)
Cash flows from financing activities:
Payments on factoring agreement	(14,946)	0
Advances on factoring agreement	15,131	0
Advances on insurance premium finance agreements	506	418
Payments on insurance premium finance agreements	(316)	(138)
Advances on debt and finance lease liabilities	1,792	0
Payments on debt and finance lease liabilities	(62)	(302)
Proceeds from common stock warrant exercises	12	1,990
Proceeds from common stock option exercises	0	147
Proceeds from issuance of common stock and pre-funded warrant, net of issuance costs	0	11,593
Net cash provided by financing activities	2,117	13,708
Net change in cash and cash equivalents and restricted cash	(5,097)	145
Cash and cash equivalents and restricted cash, beginning of period
Cash and cash equivalents	8,444	7,044
Restricted cash	0	225
Cash and cash equivalents and restricted cash, beginning of period	8,444	7,269
Cash and cash equivalents and restricted cash, end of period
Cash and cash equivalents	3,347	7,189
Restricted cash	0	225
Cash and cash equivalents and restricted cash, end of period	3,347	7,414
Supplemental disclosures:
Cash paid for interest	79	43
Cash paid for income taxes	$ 0	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2020
BASIS OF PRESENTATION [Abstract]
BASIS OF PRESENTATION	NOTE 1. BASIS OF PRESENTATION In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented. These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2019, which included all disclosures required by generally accepted accounting principles. The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business.

BUSINESS

BUSINESS	6 Months Ended
	Jun. 30, 2020
BUSINESS [Abstract]
BUSINESS	NOTE 2. BUSINESS We are a specialty ingredient company focused on producing value-added processing and marketing of healthy, natural and nutrient dense products derived from rice and other small grains, and the by-products created in the milling of these grains. Notably, we apply our proprietary technologies to convert raw rice bran into stabilized rice bran (SRB), and high value derivative products including: RiBalance, a rice bran nutritional package derived from SRB; RiSolubles, a nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance and ProRyza, a rice bran protein-based product; and a variety of other valuable derivatives extracted from these core products. In granular form, SRB is a food additive used in the production of products for both human and animal consumption. We believe SRB has certain inherent qualities that make it more attractive for this purpose than food additives based on the by-products of other agricultural commodities, such as corn and soybeans. Our SRB and refined SRB products and derivatives support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in meats, baked goods, cereals, coatings, health foods, and high-end animal nutrition. Our target customers are natural food, food and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally. We manufacture and distribute SRB in various granulations from four locations: two leased facilities located within supplier-owned rice mills in Arbuckle and West Sacramento, California; one company-owned facility in Mermentau, Louisiana; and our company-owned rice mill in Wynne, Arkansas. At our Dillon, Montana facility, we produce SRB based products and derivatives that have been further refined through our proprietary processes. Our rice mill in Wynne, Arkansas also supplies grades U.S. No. 1 and No. 2 premium long and medium white rice. We also own a grain processing facility in East Grand Forks, Minnesota, at which we mill a variety of grains which we can offer to the market.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Recent Accounting Guidance Recent accounting standards not yet adopted The following discusses the accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice. In June 2016, the Financial Accounting Standards Board (FASB) issued guidance ASU No. 2016-13 Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments Recently adopted accounting standards In December 2019, the FASB issued guidance ASU No. 2019-12 - Income Taxes (Topic 740): implifying the Accounting for Income Taxes Reclassifications Derivative Financial Instruments In May 2020, we began to use derivative financial instruments to manage a portion of our risks related to commodity prices. We do not use derivative financial instruments for trading or speculative purposes. Changes in the fair value of derivative financial instruments are recognized either in cost of goods sold or in shareholders’ equity as a component of other comprehensive income (loss) (OCI), depending on whether the derivative financial instrument is undesignated or qualifies for hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. the amount

ACQUISITION

ACQUISITION	6 Months Ended
	Jun. 30, 2020
ACQUISITION [Abstract]
ACQUISITION	NOTE 4. ACQUISITION On April 4, 2019, we acquired substantially all of the assets comprising the business of MGI Grain Processing, LLC, a Minnesota limited liability company, now conducting business as MGI Grain Incorporated (MGI) 2019. The following table provides unaudited pro forma information for the three months and six months ended June 30, 2019, as if the MGI acquisition had occurred January 1, 2019. Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Revenues (in thousands) $ 6,277 $ 13,783 Loss from continuing operations (in thousands) $ (3,803 ) $ (6,539 ) Loss per share - continuing operations $ (0.11 ) $ (0.21 ) Weighted average number of common shares outstanding - basic and diluted 33,204,332 31,382,927 No adjustments have been made in the pro forma information for synergies that are resulting or planned from the MGI acquisition. The unaudited proforma information is not indicative of the results that may have been achieved had the companies been combined as of January 1, 2018, or of our future operating results

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS	6 Months Ended
	Jun. 30, 2020
CASH AND CASH EQUIVALENTS [Abstract]
CASH AND CASH EQUIVALENTS	NOTE 5. CASH AND CASH EQUIVALENTS As of June 30, 2020, we have $2.0 million of cash and cash equivalents invested in a money market fund with net assets invested in U.S. Dollar denominated money market securities of domestic and foreign issuers, U.S. Government securities and repurchase agreements. We consider all liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. We have cash on deposit in excess of federally insured limits at a bank. We do not believe that maintaining substantially all such assets with the bank or investing in a liquid money market fund represent material risks.

ACCOUNTS RECEIVABLE AND REVENUE

ACCOUNTS RECEIVABLE AND REVENUES	6 Months Ended
	Jun. 30, 2020
ACCOUNTS RECEIVABLE AND REVENUES [Abstract]
ACCOUNTS RECEIVABLE AND REVENUES	NOTE 6. ACCOUNTS RECEIVABLE AND REVENUES Amounts billed and due from our customers are classified as accounts receivable on our consolidated balance sheets and require payment on a short-term basis. owever certain customers have terms of up to 120 days. For substantially all of our contracts, control of the ordered product(s) transfers at our location. consolidated Revenues in the three and six months ended June 30, 2020, include less than $0.1 million in revenue unearned as of December 31, 2019. Our accounts receivable potentially subject us to significant concentrations of credit risk. Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals. Customer A B C % of revenues, three months ended June 30, 2020 10 % 8 % 3 % % of revenues, three months ended June 30, 2019 10 % 14 % 1 % % of revenues, six months ended June 30, 2020 9 % 13 % 2 % % of revenues, six months ended June 30, 2019 10 % 16 % 1 % % of accounts receivable, as of June 30, 2020 14 % 32 % 8 % % of accounts receivable, as of December 31, 2019 10 % 31 % 10 % In all periods presented, less than 10% of our revenues related to shipments to locations outside of the U.S. T Three Months Ended June 30 Six Months Ended June 30 2020 2019 2020 2019 Food $ 3,967 $ 4,365 $ 10,159 $ 9,112 Animal nutrition 1,936 1,854 4,074 3,471 Revenues $ 5,903 $ 6,219 $ 14,233 $ 12,583

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2020
INVENTORIES [Abstract]
INVENTORIES	NOTE 7. INVENTORIES The following table details the components of inventories (in thousands). June 30, 2020 December 31, 2019 Finished goods $ 1,799 $ 698 Raw materials 80 90 Packaging 130 110 Inventories $ 2,009 $ 898

LEASES

LEASES	6 Months Ended
	Jun. 30, 2020
LEASES [Abstract]
LEASES	NOTE 8. LEASES The components of lease expense and cash flows from leases (amounts in thousands) follow. Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Finance lease cost: Amortization of right-of use assets, included in cost of goods sold $ 20 $ 14 $ 41 $ 18 Interest on lease liabilities 4 2 8 4 Operating lease cost, included in selling, general and administrative expenses: Fixed leases cost 131 131 261 261 Variable lease cost 33 32 48 64 Short-term lease cost - 7 3 16 Total lease cost $ 188 $ 186 $ 361 $ 363 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 4 $ 3 $ 8 $ 5 Operating cash flows from operating leases $ 131 $ 131 $ 261 $ 261 Financing cash flows from finance leases $ 20 $ 20 $ 46 $ 31 As of June 30, 2020, variable lease payments do not depend on a rate or index. As of June 30, 2020, property and equipment, net, million of finance lease right-of-use-assets, with an original cost of $0.4 million. As of June 30, 2020, we do not believe it is certain that we will exercise any renewal options. The remaining terms of our leases and the discount rates used in the calculation of the fair value of our leases as of June 30, 2020, follows. Operating Leases Finance Leases Remaining leases terms (in years) 3.3-12.7 0.6-4.0 Weighted average remaining lease terms (in years) 7.3 2.9 Discount rates 6.3%-9.0 % 4.3%-7.3 % Weighted average discount rate 7.6 % 5.8 % Maturities of lease liabilities as of June 30, 2020, follows (in thousands). Operating Finance Leases 2020 (six months ended December 31, 2020) $ 232 $ 62 2021 536 91 2022 548 68 2023 528 38 2024 428 11 Thereafter 1,469 - Total lease payments 3,741 270 Amounts representing interest (942 ) (24 ) Present value of lease obligations $ 2,799 $ 246

DEBT

DEBT	6 Months Ended
	Jun. 30, 2020
DEBT [Abstract]
DEBT	NOTE 9. DEBT In the three and six months ended June 30, 2020, we financed amounts owed for annual insurance premiums under financing agreements, due in monthly installments of principal and interest through January 2021, at interest rates of 4.7% to 5.5% per year. In October 2019, we entered into a factoring agreement which provides for a $7.0 million credit facility with a lender. We may only borrow to the extent we have qualifying accounts receivable as defined in the agreement. The facility has an initial two-year term and automatically renews for successive annual periods, unless proper termination notice is given. We paid a $0.2 million facility fee upon inception of the agreement which is amortizing to interest expense on a straight-line basis over two years. We incur recurring fees under the agreement, including a funding fee of 0.5% above the prime rate, in no event to be less than 5.5%, on any advances and a service fee on average net funds borrowed. During the three and six months ended June 30, 2020, we expensed $0.1 million and $0.2 million of interest and fees under the agreement, fees incurred averaged 4.4% (exclusive of deferred cost amortization) and interest averaged 3.2% of the amounts outstanding under the facility. During the three and six months ended June 30, 2020, outstanding borrowings under the agreement averaged $2.9 million and $2.0 million per day. Amortization of debt issuance costs in the three and six months ended June 30, 2020, was less than $0.1 million. The lender has the right to demand repayment of the advances at any time. The lender has a security interest in our personal property assets. Due under factoring agreement consists of the following (in thousands). June 30, December 31, Borrowings outstanding $ 2,174 $ 1,989 Debt issuance costs, net (121 ) (166 ) Due under factoring agreement $ 2,053 $ 1,823 Long-term debt consists of the following (in thousands). June 30, December 31, Payroll Protection Program note - Dated April 2020. Interest accrues at an annual rate of 1.0%. Due in monthly installments from November 2020 to April 2022, unless forgiven as described below. $ 1,792 $ - Equipment notes - Initially recorded in November 2018, in the acquisition of Golden Ridge, at the present value of future payments using a discount rate of 4.8% per year , which we determined approximated the market rate for similar debt with similar maturities as of the date of acquisition. Payable in monthly installments. Expire at dates ranging through 2022. 47 62 Equipment note - Dated December 2019. Due in monthly installments through December 2024. Interest accrues at the effective discount rate of 9.3% per year . 37 39 Total long term debt $ 1,876 $ 101 In April 2020, we received $1.8 million on an SBA Payroll Protection Program loan as provided for in the Coronavirus Aid, Relief and Economic Security Act (CARES), enacted into U.S. law in March 2020. Under certain conditions, the loan and accrued interest are forgivable after eight weeks as long as we use the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains payroll levels. The amount of loan forgiveness will be reduced if we terminate employees or reduce salaries during the eight-week period. The unforgiven portion of the loan is payable over two years at an interest rate of 1.0%, with a deferral of payments for the first six months. We intend to use the proceeds for purposes consistent with the program. While we currently believe that our use of the loan proceeds will meet the conditions for forgiveness of the loan, we cannot assure that we will be eligible for forgiveness of the loan, in whole or in part. In July 2020, we entered into a mortgage agreement with a lender pursuant to which we may borrow up to the lesser of (i) $2.0 million or (ii) 65% of the appraised value of our rice mill in Wynne, Arkansas which is securing the agreement. Interest accrues at an annual rate which is the greater of 11.0% above the lender’s prime rate and 14.3%. In addition, we will incur a facility fee equal to 1.0% of the amount of each advance under the agreement. We may request advances under the agreement through October 2020. The principal advances must be repaid in monthly installments ending in June 2022. Any obligations that we incur under the promissory note will be secured by certain real property and personal property assets.

EQUITY, SHARE-BASED COMPENSATIO

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	6 Months Ended
	Jun. 30, 2020
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	NOT E 10. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS In June 2020, shareholders approved, and we filed an amendment to our articles of incorporation increasing our authorized shares of common stock from 50,000,000 to 150,000,000. A summary of equity activity follows (in thousands, except share amounts). Shares Accumulated Other Preferred Common Preferred Common Accumulated Comprehensive Loss Equity Balance, December 31, 2019 225 40,074,483 $ 112 $ 318,811 $ (287,180 ) $ - $ 31,743 Common stock awards under equity incentive plans - 17,534 - 312 - - 312 Net loss - - - - (3,033 ) - (3,033 ) Balance, March 31, 2020 225 40,092,017 $ 112 $ 319,123 $ (290,213 ) $ - $ 29,022 Common stock awards under equity incentive plans - 16,500 - 316 - - 316 Commn stock issued to vendors - 31,304 - 36 - - 36 Exercise of common stock warrants - 67,577 - 12 - - 12 Other comprehensive loss - - - - - (48 ) (48 ) Net loss - - - - (3,949 ) - (3,949 ) Balance, June 30, 2020 225 40,207,398 $ 112 $ 319,487 $ (294,162 ) $ (48 ) $ 25,389 Shares Preferred Common Preferred Common Accumulated Equity Balance, December 31, 2018 405 29,098,207 $ 201 $ 296,739 $ (273,229 ) $ 23,711 Proceeds from sale of common stock and prefunded warrant, net of costs - 3,046,668 - 11,593 - 11,593 Common stock awards under equity incentive plans - 36,881 - 364 - 364 Exercise of common stock warrants - 600,000 - 1,980 - 1,980 Conversion of preferred stock into common stock (180 ) 170,818 (89 ) 89 - - Exercise of common stock options - 77,078 - 60 - 60 Other - - - 28 - 28 Net loss - - - - (3,227 ) (3,227 ) Balance, March 31, 2019 225 33,029,652 112 310,853 (276,456 ) 34,509 Exercise of prefunded warrant - 1,003,344 - 10 - 10 Common stock awards under equity incentive plans - 134,984 - 219 - 219 Exercise of common stock options - 78,734 - 87 - 87 Other - - - 32 - 32 Net loss - - - - (3,659 ) (3,659 ) Balance, June 30, 2019 225 34,246,714 $ 112 $ 311,201 $ (280,115 ) $ 31,198 On March 30, 2020, we entered into an at market issuance sales agreement with respect to an at-the-market offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million through B. Riley FBR, Inc, as sales agent. The issuance and sale, if any, of our common stock under the agreement will be made pursuant to our effective “shelf” registration statement on Form S-3. No sales made to date under this agreement We have deferred $0.1 million of legal expenses and other costs related to the offering which are included in other current assets in our consolidated balance sheets as of June 30, 2020. Share-based compensation by type of award follows (in thousands). Three Months Ended June 30, 2020 March 31, 2020 Common stock, vested at issuance and nonvested at issuance $ 95 $ 105 Stock options 99 85 Restricted stock units 122 122 Compensation expense related to common stock awards issued under equity incentive plan $ 316 $ 312 In the three months ended March 31, 2020, we issued 17,534 shares of common stock, vested at issuance, to a consultant at a grant date fair value of $1.11 per share and recognized $0.1 million of expense for shares of common stock vesting during the period. In the three months ended June 30, 2020, under the equity incentive plan, we issued 16,500 shares of common stock, vested at June 30, 2020, at a grant date fair value or $1.16 per shares and (ii) recognized $0.1 million of expense for shares of common stock vesting during the period. As of June 30, 2020, there was no shares of nonvested common stock outstanding. In the three months ended June 30, 2020, we issued 31,304 shares of common stock to a vendor, vested at June 30, 2020, at a grant date fair value or $1.14 per share. Stock option activity for the six months ended June 30, 2020, follows. Shares Under Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding at December 31, 2019 996,009 $ 3.23 8.1 Granted 653,004 1.22 $ 0.73 10.0 Forfeited (125,173 ) 4.74 7.2 Outstanding at March 31, 2020 1,523,840 2.24 8.8 Forfeited (77,357 ) 4.28 7.2 Outstanding at June 30, 2020 1,446,483 $ 2.13 8.6 Stock options granted in the three months ended March 31, 2020, each vest and become exercisable in annual installments ending four years from the date of grant and were valued using methods and assumptions comparable to those for our 2019 stock option grants. Restricted stock unit (RSU) activity for the six months ended June 30, 2020, follows. RSU Shares Issued to Employees and Directors Unrecognized Stock Compensation (in thousands) Weighted Average Expense Period (Years) Nonvested at December 31, 2019 1,148,062 $ 377 1.4 Cancelled (625,000 ) - Forfeited (1) (175,000 ) (142 ) Expensed (2) - (122 ) Nonvested at March 31, 2020 348,062 113 1.2 Granted to Directors (3) 477,018 426 Forfeited (30,000 ) (24 ) Vested (4) (115,904 ) - Expensed - (122 ) Nonvested at June 30, 2020 (5)(6) 679,176 $ 393 0.8 (1) In the three months ended March 31, 2020, we reversed $0.1 million of expense recognized prior to January 1, 2020 on forfeited RSU shares. (2) We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares. (3) The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies. (4) Represents shares of common stock subject to RSUs which were vested when granted. (5) RSUs for a total of 361,114 shares of common stock vest in June 2021, and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies. (6) A total of 318,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 31,806 shares on the date the vesting price equals or exceeds $5.00 per share (ii) 95,419 shares the date the vesting price equals or exceeds $10.00 per share and (iii) 190,837 shares the date the vesting price equals or exceeds $15.00 per share. Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence. The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024. Warrant activity for the six months ended June 30, 2020, follows. Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Outstanding, December 31, 2019 7,532,280 $ 1.32 1.9 Expired (265,000 ) 5.25 - Outstanding, March 31, 2020 7,267,280 1.18 1.7 Cash exercised (12,948 ) 0.96 - Cashless exercised (1) (215,740 ) 0.96 - Expired (392,676 ) 4.60 - Outstanding, June 30, 2020 (2) 6,645,916 $ 0.98 1.7 (1) In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants. (2) Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. As of June 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an average exercise price of $5.25 per share. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2020
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 11. INCOME TAXES Our tax expense for the three and six months ended June 30, 2020 and 2019, differs from the tax expense computed by applying the U.S. statutory tax rate to net loss from continuing operations before income taxes as no tax benefits were recorded for tax losses generated in the U.S. As of June 30, 2020, we had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards. We provided a full valuation allowance against our deferred tax assets as future realization of such assets is not more likely than not to occur. Based on an analysis of tax positions taken on income tax returns filed, we have determined no material liabilities related to uncertain income tax positions exist. Although we believe the amounts reflected in our tax returns substantially comply with applicable U.S. federal, state, and foreign tax regulations, the respective taxing authorities may take contrary positions based on their interpretation of the law. A tax position successfully challenged by a taxing authority could result in an adjustment to our provision or benefit for income taxes in the period in which a final determination is made. CARES, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds and modifications to the net interest deduction limitations. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment. Except for the impact of the loan we received under the act, see Note 9, we do not anticipate that the act will have a material impact on our financial position, results of operations or cash flows.

LOSS PER SHARE (EPS)

LOSS PER SHARE (EPS)	6 Months Ended
	Jun. 30, 2020
LOSS PER SHARE (EPS) [Abstract]
LOSS PER SHARE (EPS)	NOTE 12. LOSS PER SHARE (EPS) Basic EPS is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends. Our outstanding convertible preferred stock are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses. Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies common shareholders by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive. The dilutive effects of outstanding options, warrants, nonvested shares of common stock and nonvested restricted stock units that vest solely on the basis of a service condition are calculated using the treasury stock method. The dilutive effects of the outstanding preferred stock are calculated using the if-converted method. Below are reconciliations of the numerators and denominators in the EPS computations. Three Months Ended June 30 Six Months Ended June 30 2020 2019 2020 2019 NUMERATOR (in thousands): Basic and diluted - loss from continuing operations $ (3,949 ) $ (3,659 ) $ (6,982 ) $ (6,670 ) DENOMINATOR: Weighted average number of shares of shares of common stock outstanding 40,041,888 33,204,332 40,002,522 31,382,927 Weighted average number of shares of common stock underlying vested restricted stock units 10,275 - 5,138 - Basic EPS - weighted average number of shares outstanding 40,052,163 33,204,332 40,007,660 31,382,927 Effect of dilutive securities outstanding - - - - Diluted EPS - weighted average number of shares outstanding 40,052,163 33,204,332 40,007,660 31,382,927 No effects of potentially dilutive securities outstanding during the three and six months ended June 30, 2020 and 2019, were included in the calculation of diluted EPS for the three and six months ended June 30, 2020 and 2019 because to do so would be anti-dilutive as a results of our loss from continuing operations. Potentially dilutive securities outstanding during the periods included our outstanding convertible preferred stock, options, warrants, nonvested restricted stock units and nonvested stock. Those potentially dilutive securities, further described in Note 10, could potentially dilute EPS in the future.

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2020
DERIVATIVE FINANCIAL INSTRUMENTS [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS	NOTE 13. DERIVATIVE FINANCIAL INSTRUMENTS As of June 30, 2020, our outstanding derivative financial instruments consist of commodity futures which trade on a major exchange. As of June 30, 2020, other current assets include a $0.5 million receivable representing our margin account with a broker. We are potentially exposed to credit risk under the futures but not for the notional amounts. We are exposed to credit risk to the extent the open futures are in an asset position. At June 30, 2020, the fair value of open futures was a negative $48 thousand (recorded in accumulated OCI) and, therefore, we had no credit risk associated with those open derivative financial instruments.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2020
FAIR VALUE MEASUREMENTS [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 14. FAIR VALUE MEASUREMENTS Derivative financial instruments are carried at fair value, on a recurring basis, in accumulated OCI, and fair value is based on the quoted prices of the financial instruments (Level 1 measurements). The fair value of cash and cash equivalents, restricted cash, accounts and other receivables, accounts payable, commodities payable and short-term debt approximated their carrying value due to shorter maturities. As of June 30, 2020, the fair values of our operating lease liabilities was approximately $0.1 million higher than their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements). As of June 30, 2020, the fair values of our long-term debt and finance lease liabilities approximated their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2020
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 15. COMMITMENTS AND CONTINGENCIES Employment Contracts and Severance Payments In the normal course of business, we periodically enter into employment agreements which incorporate indemnification provisions. While the maximum amount to which we may be exposed under such agreements cannot be reasonably estimated, we maintain insurance coverage, which we believe will effectively mitigate our obligations under these indemnification provisions. No amounts have been recorded in our financial statements with respect to any obligations under such agreements. We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control. In addition, vesting of outstanding nonvested equity grants would accelerate following a change in control. Legal Matters From time to time we are involved in litigation incidental to the conduct of our business. These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations. When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. Defense costs are expensed as incurred and are included in professional fees. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations, except for a contract dispute settled in July 2020 for $0.2 million. In the three months ended June 30, 2020, we included $0.2 million in cost of goods sold and as of June 30, 2020, included a $0.2 million liability in

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2020
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 16. RELATED PARTY TRANSACTIONS Our director, Ari Gendason, is an employee and senior vice president and chief investment officer of Continental Grain Company (CGC). As of the date of this filing, CGC owns approximately 26.5% of our outstanding common stock. We have a greed that in connection with each annual or special meeting of our shareholders at which members of our board of directors are to be elected, or any written consent of our shareholders pursuant to which members of the board of directors are to be elected, CGC shall have the right to designate one nominee to our board of directors. exercisable into 1,003,344 shares of common stock for $2.99 per share, in a private placement. The prefunded warrant had an exercise price of $0.01 per share and was immediately exercisable; however, we had to obtain approval from our shareholders before CGC could exercise the prefunded warrant to the extent such exercise would result in the holder owning in excess of 19.99% of our common shares outstanding. CGC exercised the entire prefunded warrant automatically when our shareholders approved the exercise in June 2019.

TRANSACTIONS WITH EMPLOYEES

TRANSACTIONS WITH EMPLOYEES	6 Months Ended
	Jun. 30, 2020
TRANSACTIONS WITH EMPLOYEES [Abstract]
TRANSACTIONS WITH EMPLOYEES	NOTE 17. TRANSACTIONS WITH EMPLOYEES During the six months ended June 30, 2019, and three months ended March 31, 2019, we paid $1.4 million to entities owned by our former employee, Wayne Wilkison. As of June 30, 2020, and December 31, 2019, no amounts were owed to these entities.

FAILURE TO COMPLY WITH NASDAQ L

FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS	6 Months Ended
	Jun. 30, 2020
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS	NOTE 18. FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS On July 27, 2020, we received a notification letter from The Nasdaq Stock Market LLC (Nasdaq) indicating that we have failed to comply with the minimum bid price requirement of Nasdaq List Rule 5550(a)(2). Nasdaq Listing Rule 5550(a)(2) requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00. To regain compliance with this listing rule, the closing bid price of our common stock must be at least $1.00 for 10 consecutive business days. Nasdaq rules allow for a compliance period of 180 calendar days, or until January 25, 2021 in which to regain compliance. If this appears unlikely as January 25, 2021 approaches, we are committed to taking actions that would enable us to regain compliance, including, if necessary, completing a reverse split of our common stock to increase its share price above the $1.00 minimum bid price.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2020
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	NOTE 19. SUBSEQUENT EVENTS On August 11, 2020, RiceBran Technologies and Mr. Brent Rystrom entered into a separation and release agreement which provides that, effective August 14, 2020, Mr. Rystrom resigns as our employee, chief executive officer, and director. We will retain Mr. Rystrom as a consultant through December 31, 2020, and Mr. Rystrom will receive medical and insurance benefits during this period. On August 11, 2020, our board of directors appointed Peter G. Bradley to the role of executive chairman effective August 14, 2020. In this role, Mr. Bradley will oversee our day-to-day operations as well as coordinate a review of strategic alternatives. Mr. Bradley is a global business leader with more than 23 years of experience as an executive in various food and ingredients businesses. Most recently, Mr. Bradley has been a principal at Ingredient Insights, a strategic consultant focused on food ingredients and is currently an operating partner at Arbor Investments, a private equity firm that focuses exclusively on acquiring premier companies in the food, beverage and related industries. On August 11, 2020, our board of directors appointed Brent Rosenthal to serve in the capacity of lead independent director effective August 14, 2020.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2020
BASIS OF PRESENTATION [Abstract]
Basis of Presentation	In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented. These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2019, which included all disclosures required by generally accepted accounting principles. The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Recent Accounting Guidance	Recent Accounting Guidance Recent accounting standards not yet adopted The following discusses the accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice. In June 2016, the Financial Accounting Standards Board (FASB) issued guidance ASU No. 2016-13 Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments Recently adopted accounting standards In December 2019, the FASB issued guidance ASU No. 2019-12 - Income Taxes (Topic 740): implifying the Accounting for Income Taxes
Reclassifications	Reclassifications
Derivative Financial Instruments	Derivative Financial Instruments In May 2020, we began to use derivative financial instruments to manage a portion of our risks related to commodity prices. We do not use derivative financial instruments for trading or speculative purposes. Changes in the fair value of derivative financial instruments are recognized either in cost of goods sold or in shareholders’ equity as a component of other comprehensive income (loss) (OCI), depending on whether the derivative financial instrument is undesignated or qualifies for hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. the amount

ACQUISITION (Tables)

ACQUISITION (Tables)	6 Months Ended
	Jun. 30, 2020
MGI Grain Processing LLC [Member]
Business Acquisition [Line Items]
Pro Forma Financial Information	The following table provides unaudited pro forma information for the three months and six months ended June 30, 2019, as if the MGI acquisition had occurred January 1, 2019. Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Revenues (in thousands) $ 6,277 $ 13,783 Loss from continuing operations (in thousands) $ (3,803 ) $ (6,539 ) Loss per share - continuing operations $ (0.11 ) $ (0.21 ) Weighted average number of common shares outstanding - basic and diluted 33,204,332 31,382,927

ACCOUNTS RECEIVABLE AND REVEN_2

ACCOUNTS RECEIVABLE AND REVENUES (Tables)	6 Months Ended
	Jun. 30, 2020
ACCOUNTS RECEIVABLE AND REVENUES [Abstract]
Concentrations of Risk	Our accounts receivable potentially subject us to significant concentrations of credit risk. Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals. Customer A B C % of revenues, three months ended June 30, 2020 10 % 8 % 3 % % of revenues, three months ended June 30, 2019 10 % 14 % 1 % % of revenues, six months ended June 30, 2020 9 % 13 % 2 % % of revenues, six months ended June 30, 2019 10 % 16 % 1 % % of accounts receivable, as of June 30, 2020 14 % 32 % 8 % % of accounts receivable, as of December 31, 2019 10 % 31 % 10 %
Revenues by Product Line	In all periods presented, less than 10% of our revenues related to shipments to locations outside of the U.S. T Three Months Ended June 30 Six Months Ended June 30 2020 2019 2020 2019 Food $ 3,967 $ 4,365 $ 10,159 $ 9,112 Animal nutrition 1,936 1,854 4,074 3,471 Revenues $ 5,903 $ 6,219 $ 14,233 $ 12,583

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2020
INVENTORIES [Abstract]
Components of Inventories	The following table details the components of inventories (in thousands). June 30, 2020 December 31, 2019 Finished goods $ 1,799 $ 698 Raw materials 80 90 Packaging 130 110 Inventories $ 2,009 $ 898

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2020
LEASES [Abstract]
Components of Lease Expense	The components of lease expense and cash flows from leases (amounts in thousands) follow. Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Finance lease cost: Amortization of right-of use assets, included in cost of goods sold $ 20 $ 14 $ 41 $ 18 Interest on lease liabilities 4 2 8 4 Operating lease cost, included in selling, general and administrative expenses: Fixed leases cost 131 131 261 261 Variable lease cost 33 32 48 64 Short-term lease cost - 7 3 16 Total lease cost $ 188 $ 186 $ 361 $ 363 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 4 $ 3 $ 8 $ 5 Operating cash flows from operating leases $ 131 $ 131 $ 261 $ 261 Financing cash flows from finance leases $ 20 $ 20 $ 46 $ 31
Remaining Lease Term and Discount Rate	The remaining terms of our leases and the discount rates used in the calculation of the fair value of our leases as of June 30, 2020, follows. Operating Leases Finance Leases Remaining leases terms (in years) 3.3-12.7 0.6-4.0 Weighted average remaining lease terms (in years) 7.3 2.9 Discount rates 6.3%-9.0 % 4.3%-7.3 % Weighted average discount rate 7.6 % 5.8 %
Maturities of Lease Liabilities	Maturities of lease liabilities as of June 30, 2020, follows (in thousands). Operating Finance Leases 2020 (six months ended December 31, 2020) $ 232 $ 62 2021 536 91 2022 548 68 2023 528 38 2024 428 11 Thereafter 1,469 - Total lease payments 3,741 270 Amounts representing interest (942 ) (24 ) Present value of lease obligations $ 2,799 $ 246

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jun. 30, 2020
DEBT [Abstract]
Dues Under Factoring Agreement	Due under factoring agreement consists of the following (in thousands). June 30, December 31, Borrowings outstanding $ 2,174 $ 1,989 Debt issuance costs, net (121 ) (166 ) Due under factoring agreement $ 2,053 $ 1,823
Long-term Debt	Long-term debt consists of the following (in thousands). June 30, December 31, Payroll Protection Program note - Dated April 2020. Interest accrues at an annual rate of 1.0%. Due in monthly installments from November 2020 to April 2022, unless forgiven as described below. $ 1,792 $ - Equipment notes - Initially recorded in November 2018, in the acquisition of Golden Ridge, at the present value of future payments using a discount rate of 4.8% per year , which we determined approximated the market rate for similar debt with similar maturities as of the date of acquisition. Payable in monthly installments. Expire at dates ranging through 2022. 47 62 Equipment note - Dated December 2019. Due in monthly installments through December 2024. Interest accrues at the effective discount rate of 9.3% per year . 37 39 Total long term debt $ 1,876 $ 101

EQUITY, SHARE-BASED COMPENSAT_2

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2020
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
Equity Activity	A summary of equity activity follows (in thousands, except share amounts). Shares Accumulated Other Preferred Common Preferred Common Accumulated Comprehensive Loss Equity Balance, December 31, 2019 225 40,074,483 $ 112 $ 318,811 $ (287,180 ) $ - $ 31,743 Common stock awards under equity incentive plans - 17,534 - 312 - - 312 Net loss - - - - (3,033 ) - (3,033 ) Balance, March 31, 2020 225 40,092,017 $ 112 $ 319,123 $ (290,213 ) $ - $ 29,022 Common stock awards under equity incentive plans - 16,500 - 316 - - 316 Commn stock issued to vendors - 31,304 - 36 - - 36 Exercise of common stock warrants - 67,577 - 12 - - 12 Other comprehensive loss - - - - - (48 ) (48 ) Net loss - - - - (3,949 ) - (3,949 ) Balance, June 30, 2020 225 40,207,398 $ 112 $ 319,487 $ (294,162 ) $ (48 ) $ 25,389 Shares Preferred Common Preferred Common Accumulated Equity Balance, December 31, 2018 405 29,098,207 $ 201 $ 296,739 $ (273,229 ) $ 23,711 Proceeds from sale of common stock and prefunded warrant, net of costs - 3,046,668 - 11,593 - 11,593 Common stock awards under equity incentive plans - 36,881 - 364 - 364 Exercise of common stock warrants - 600,000 - 1,980 - 1,980 Conversion of preferred stock into common stock (180 ) 170,818 (89 ) 89 - - Exercise of common stock options - 77,078 - 60 - 60 Other - - - 28 - 28 Net loss - - - - (3,227 ) (3,227 ) Balance, March 31, 2019 225 33,029,652 112 310,853 (276,456 ) 34,509 Exercise of prefunded warrant - 1,003,344 - 10 - 10 Common stock awards under equity incentive plans - 134,984 - 219 - 219 Exercise of common stock options - 78,734 - 87 - 87 Other - - - 32 - 32 Net loss - - - - (3,659 ) (3,659 ) Balance, June 30, 2019 225 34,246,714 $ 112 $ 311,201 $ (280,115 ) $ 31,198
Share-based Compensation by Type of Award	Share-based compensation by type of award follows (in thousands). Three Months Ended June 30, 2020 March 31, 2020 Common stock, vested at issuance and nonvested at issuance $ 95 $ 105 Stock options 99 85 Restricted stock units 122 122 Compensation expense related to common stock awards issued under equity incentive plan $ 316 $ 312
Stock Option Activity	Stock option activity for the six months ended June 30, 2020, follows. Shares Under Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding at December 31, 2019 996,009 $ 3.23 8.1 Granted 653,004 1.22 $ 0.73 10.0 Forfeited (125,173 ) 4.74 7.2 Outstanding at March 31, 2020 1,523,840 2.24 8.8 Forfeited (77,357 ) 4.28 7.2 Outstanding at June 30, 2020 1,446,483 $ 2.13 8.6
RSU Activity	Restricted stock unit (RSU) activity for the six months ended June 30, 2020, follows. RSU Shares Issued to Employees and Directors Unrecognized Stock Compensation (in thousands) Weighted Average Expense Period (Years) Nonvested at December 31, 2019 1,148,062 $ 377 1.4 Cancelled (625,000 ) - Forfeited (1) (175,000 ) (142 ) Expensed (2) - (122 ) Nonvested at March 31, 2020 348,062 113 1.2 Granted to Directors (3) 477,018 426 Forfeited (30,000 ) (24 ) Vested (4) (115,904 ) - Expensed - (122 ) Nonvested at June 30, 2020 (5)(6) 679,176 $ 393 0.8 (1) In the three months ended March 31, 2020, we reversed $0.1 million of expense recognized prior to January 1, 2020 on forfeited RSU shares. (2) We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares. (3) The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies. (4) Represents shares of common stock subject to RSUs which were vested when granted. (5) RSUs for a total of 361,114 shares of common stock vest in June 2021, and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies. (6) A total of 318,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 31,806 shares on the date the vesting price equals or exceeds $5.00 per share (ii) 95,419 shares the date the vesting price equals or exceeds $10.00 per share and (iii) 190,837 shares the date the vesting price equals or exceeds $15.00 per share. Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence. The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.
Warrant Activity	Warrant activity for the six months ended June 30, 2020, follows. Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Outstanding, December 31, 2019 7,532,280 $ 1.32 1.9 Expired (265,000 ) 5.25 - Outstanding, March 31, 2020 7,267,280 1.18 1.7 Cash exercised (12,948 ) 0.96 - Cashless exercised (1) (215,740 ) 0.96 - Expired (392,676 ) 4.60 - Outstanding, June 30, 2020 (2) 6,645,916 $ 0.98 1.7 (1) In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants. (2) Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. As of June 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an average exercise price of $5.25 per share. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature.

LOSS PER SHARE (EPS) (Tables)

LOSS PER SHARE (EPS) (Tables)	6 Months Ended
	Jun. 30, 2020
LOSS PER SHARE (EPS) [Abstract]
Reconciliations of Numerators and Denominators in EPS Computations	Below are reconciliations of the numerators and denominators in the EPS computations. Three Months Ended June 30 Six Months Ended June 30 2020 2019 2020 2019 NUMERATOR (in thousands): Basic and diluted - loss from continuing operations $ (3,949 ) $ (3,659 ) $ (6,982 ) $ (6,670 ) DENOMINATOR: Weighted average number of shares of shares of common stock outstanding 40,041,888 33,204,332 40,002,522 31,382,927 Weighted average number of shares of common stock underlying vested restricted stock units 10,275 - 5,138 - Basic EPS - weighted average number of shares outstanding 40,052,163 33,204,332 40,007,660 31,382,927 Effect of dilutive securities outstanding - - - - Diluted EPS - weighted average number of shares outstanding 40,052,163 33,204,332 40,007,660 31,382,927

BUSINESS (Details)

BUSINESS (Details)	Jun. 30, 2020Location
BUSINESS [Abstract]
Number of locations	4
Number of locations in California	2
Number of locations in Louisiana	1

ACQUISITION (Details)

ACQUISITION (Details) - MGI Grain Processing LLC [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Business Acquisition, Pro Forma Information [Abstract]
Revenues	$ 6,277	$ 13,783
Loss from continuing operations	$ (3,803)	$ (6,539)
Loss per share - continuing operations (in dollars per share)	$ (0.11)	$ (0.21)
Weighted average number of common shares outstanding - basic and diluted (in shares)	33,204,332	31,382,927

CASH AND CASH EQUIVALENTS (Deta

CASH AND CASH EQUIVALENTS (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 3,347	$ 8,444	$ 7,189	$ 7,044
Money Market Funds [Member]
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 2,000

ACCOUNTS RECEIVABLE AND REVEN_3

ACCOUNTS RECEIVABLE AND REVENUES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Concentration of Credit Risk [Abstract]
Revenues	$ 5,903	$ 6,219	$ 14,233	$ 12,583
Revenue unearned	0		$ 0		$ 12
Minimum [Member]
Concentration of Credit Risk [Abstract]
Receivables payment term			30 days
Maximum [Member]
Concentration of Credit Risk [Abstract]
Receivables payment term			120 days
Revenue unearned	100		$ 100
Operating Segments [Member] | Food [Member]
Concentration of Credit Risk [Abstract]
Revenues	3,967	4,365	10,159	9,112
Operating Segments [Member] | Animal Nutrition [Member]
Concentration of Credit Risk [Abstract]
Revenues	$ 1,936	$ 1,854	$ 4,074	$ 3,471
Customer A [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	10.00%	10.00%	9.00%	10.00%
Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage			14.00%		10.00%
Customer B [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	8.00%	14.00%	13.00%	16.00%
Customer B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage			32.00%		31.00%
Customer C [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage	3.00%	1.00%	2.00%	1.00%
Customer C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration of Credit Risk [Abstract]
Concentration risk, percentage			8.00%		10.00%

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Inventories [Abstract]
Finished goods	$ 1,799	$ 698
Raw materials	80	90
Packaging	130	110
Inventories	$ 2,009	$ 898

LEASES (Details)

LEASES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Finance lease cost [Abstract]
Amortization of right-of use assets, included in cost of goods sold	$ 20	$ 14	$ 41	$ 18
Interest on lease liabilities	4	2	8	4
Operating lease cost, included in selling, general and administrative expenses [Abstract]
Fixed leases cost	131	131	261	261
Variable lease cost	33	32	48	64
Short-term lease cost	0	7	3	16
Total lease cost	188	186	361	363
Cash paid for amounts included in the measurement of lease liabilities [Abstract]
Operating cash flows from finance leases	4	3	8	5
Operating cash flows from operating leases	131	131	261	261
Financing cash flows from finance leases	20	$ 20	46	$ 31
Finance lease right-of-use-assets, net	$ 300		$ 300
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:PropertyPlantAndEquipmentNet		us-gaap:PropertyPlantAndEquipmentNet
Finance lease right-of-use-assets, original cost	$ 400		$ 400
Operating Leases [Abstract]
Weighted average remaining lease terms (in years)	7 years 3 months 18 days		7 years 3 months 18 days
Weighted average discount rate	7.60%		7.60%
Finance Leases [Abstract]
Weighted average remaining lease terms (in years)	2 years 10 months 24 days		2 years 10 months 24 days
Weighted average discount rate	5.80%		5.80%
Maturities of Operating Lease Liabilities [Abstract]
2020 (six months ended December 31, 2020)	$ 232		$ 232
2021	536		536
2022	548		548
2023	528		528
2024	428		428
Thereafter	1,469		1,469
Total lease payments	3,741		3,741
Amounts representing interest	(942)		(942)
Present value of lease obligations	2,799		2,799
Maturities of Finance Lease Liabilities [Abstract]
2020 (six months ended December 31, 2020)	62		62
2021	91		91
2022	68		68
2023	38		38
2024	11		11
Thereafter	0		0
Total lease payments	270		270
Amounts representing interest	(24)		(24)
Present value of lease obligations	$ 246		$ 246
Minimum [Member]
Operating Leases [Abstract]
Remaining leases terms (in years)			3 years 3 months 18 days
Discount rate	6.30%		6.30%
Finance Leases [Abstract]
Remaining leases terms (in years)			7 months 6 days
Discount rate	4.30%		4.30%
Maximum [Member]
Operating Leases [Abstract]
Remaining leases terms (in years)			12 years 8 months 12 days
Discount rate	9.00%		9.00%
Finance Leases [Abstract]
Remaining leases terms (in years)			4 years
Discount rate	7.30%		7.30%

DEBT (Details)

DEBT (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	6 Months Ended
	Jul. 31, 2020	Oct. 31, 2019	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Due under Factoring Agreement [Abstract]
Due under factoring agreement			$ 2,053	$ 2,053	$ 1,823
Long-term Debt [Abstract]
Total long-term debt			$ 1,876	$ 1,876	101
Minimum [Member]
Debt Instruments [Abstract]
Long term debt interest rate			4.70%	4.70%
Interest rate			4.70%	4.70%
Maximum [Member]
Debt Instruments [Abstract]
Long term debt interest rate			5.50%	5.50%
Interest rate			5.50%	5.50%
Factoring Agreement [Member]
Due under Factoring Agreement [Abstract]
Borrowing outstanding			$ 2,174	$ 2,174	1,989
Debt issuance costs, net			(121)	(121)	(166)
Due under factoring agreement			$ 2,053	$ 2,053	1,823
Factoring Agreement [Member] | Line of Credit [Member]
Debt Instruments [Abstract]
Line of credit facility, maximum borrowing capacity		$ 7,000
Line of credit facility, initial term				2 years
Facility fee, amount		$ 200
Percentage of funding fee			0.50%	0.50%
Interest and fees expense			$ 100	$ 200
Fees incurred averaged percentage			4.40%	4.40%
Interest averaged percentage			3.20%	3.20%
Outstanding borrowings average amount			$ 2,900	$ 2,000
Factoring Agreement [Member] | Line of Credit [Member] | Minimum [Member]
Debt Instruments [Abstract]
Line of credit facility, recurring fee		5.50%
Factoring Agreement [Member] | Line of Credit [Member] | Maximum [Member]
Debt Instruments [Abstract]
Amortization of debt issuance costs			$ 100	$ 100
Paycheck Protection Program [Member] | Notes Payable [Member]
Debt Instruments [Abstract]
Long term debt interest rate			1.00%	1.00%
Maturity date of note start				Nov. 30, 2020
Maturity date of note end				Apr. 30, 2022
Interest rate			1.00%	1.00%
Long-term Debt [Abstract]
Total long-term debt			$ 1,792	$ 1,792	0
Equipment Notes, November 2018 [Member] | Notes Payable [Member]
Debt Instruments [Abstract]
Long term debt interest rate			4.80%	4.80%
Maturity date				Dec. 31, 2022
Interest rate			4.80%	4.80%
Long-term Debt [Abstract]
Total long-term debt			$ 47	$ 47	62
Equipment Notes, December 2019 [Member] | Notes Payable [Member]
Debt Instruments [Abstract]
Long term debt interest rate			9.30%	9.30%
Maturity date				Dec. 31, 2024
Interest rate			9.30%	9.30%
Long-term Debt [Abstract]
Total long-term debt			$ 37	$ 37	$ 39
Mortgage Agreement [Member]
Debt Instruments [Abstract]
Maturity date	Jun. 30, 2022
Mortgage Agreement [Member] | Subsequent Event [Member]
Debt Instruments [Abstract]
Long term debt interest rate	14.30%
Line of credit facility, maximum borrowing capacity	$ 2,000
Maximum percentage of credit facility available on appraised value of real property	65.00%
Interest rate	14.30%
Credit facility fee percentage on amount of each advance	1.00%
Mortgage Agreement [Member] | Minimum [Member] | Subsequent Event [Member] | Prime Rate [Member]
Debt Instruments [Abstract]
Accrued interest on borrowings at annual rate	11.00%

EQUITY, SHARE-BASED COMPENSAT_3

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Summary of Equity Activity (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	May 31, 2020	Dec. 31, 2019
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]
Common stock, shares authorized (in shares)	150,000,000				150,000,000		50,000,000	150,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 29,022	$ 31,743	$ 34,509	$ 23,711	$ 31,743	$ 23,711
Balance (in shares)		40,074,483			40,074,483
Proceeds from sale of common stock and prefunded warrant, net of costs				11,593
Exercise of Prefunded Warrant			10
Common stock awards under equity incentive plans	316	$ 312	219	364
Common stock issued to vendors	36
Exercise of common stock warrants	12			1,980
Conversion of preferred stock into common stock				0
Exercise of common stock options			87	60
Other			32	28
Other comprehensive loss	(48)		0		$ (48)	0
Net loss	(3,949)	(3,033)	(3,659)	(3,227)	(6,982)	(6,886)
Balance	$ 25,389	29,022	31,198	34,509	$ 25,389	31,198
Balance (in shares)	40,207,398				40,207,398
Preferred Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 112	112	112	201	$ 112	201
Proceeds from sale of common stock and prefunded warrant, net of costs				0
Exercise of Prefunded Warrant			0
Common stock awards under equity incentive plans	0	0	0	0
Common stock issued to vendors	0
Exercise of common stock warrants	0			0
Conversion of preferred stock into common stock				(89)
Exercise of common stock options			0	0
Other			0	0
Other comprehensive loss	0
Net loss	0	0	0	0
Balance	$ 112	$ 112	$ 112	$ 112	$ 112	$ 112
Preferred Stock [Member] | Series G Preferred Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance (in shares)	225	225	225	405	225	405
Proceeds from sale of common stock and prefunded warrant, net of costs (in shares)				0
Exercise of Prefunded Warrant (in shares)			0
Common stock awards under equity incentive plans (in shares)	0	0	0	0
Common stock issued to vendors (in shares)	0
Exercise of common stock warrants (in shares)	0			0
Conversion of preferred stock into common stock (in shares)				(180)
Exercise of common stock options (in shares)			0	0
Other (in shares)			0	0
Balance (in shares)	225	225	225	225	225	225
Common Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 319,123	$ 318,811	$ 310,853	$ 296,739	$ 318,811	$ 296,739
Balance (in shares)	40,092,017	40,074,483	33,029,652	29,098,207	40,074,483	29,098,207
Proceeds from sale of common stock and prefunded warrant, net of costs				$ 11,593
Proceeds from sale of common stock and prefunded warrant, net of costs (in shares)				3,046,668
Exercise of Prefunded Warrant			$ 10
Exercise of Prefunded Warrant (in shares)			1,003,344
Common stock awards under equity incentive plans	$ 316	$ 312	$ 219	$ 364
Common stock awards under equity incentive plans (in shares)	16,500	17,534	134,984	36,881
Common stock issued to vendors	$ 36
Common stock issued to vendors (in shares)	31,304
Exercise of common stock warrants	$ 12			$ 1,980
Exercise of common stock warrants (in shares)	67,577			600,000
Conversion of preferred stock into common stock				$ 89
Conversion of preferred stock into common stock (in shares)				170,818
Exercise of common stock options			$ 87	$ 60
Exercise of common stock options (in shares)			78,734	77,078
Other			$ 32	$ 28
Other (in shares)			0	0
Other comprehensive loss	$ 0
Net loss	0	$ 0	$ 0	$ 0
Balance	$ 319,487	$ 319,123	$ 311,201	$ 310,853	$ 319,487	$ 311,201
Balance (in shares)	40,207,398	40,092,017	34,246,714	33,029,652	40,207,398	34,246,714
Accumulated Deficit [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ (290,213)	$ (287,180)	$ (276,456)	$ (273,229)	$ (287,180)	$ (273,229)
Proceeds from sale of common stock and prefunded warrant, net of costs				0
Exercise of Prefunded Warrant			0
Common stock awards under equity incentive plans	0	0	0	0
Common stock issued to vendors	0
Exercise of common stock warrants	0			0
Conversion of preferred stock into common stock				0
Exercise of common stock options			0	0
Other			0	0
Other comprehensive loss	0
Net loss	(3,949)	(3,033)	(3,659)	(3,227)
Balance	(294,162)	(290,213)	$ (280,115)	$ (276,456)	(294,162)	$ (280,115)
Accumulated Other Comprehensive Loss [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	0	0			0
Common stock awards under equity incentive plans	0	0
Common stock issued to vendors	0
Exercise of common stock warrants	0
Other comprehensive loss	(48)
Net loss	0	0
Balance	$ (48)	$ 0			$ (48)

EQUITY, SHARE-BASED COMPENSAT_4

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Sales Agreement (Details) - At-the-Market Offering [Member] $ in Millions	Mar. 30, 2020USD ($)
Share Based Compensation Arrangement By Share Based Payment Award Information [Abstract]
Deferred offering costs, legal expenses and other costs	$ 0.1
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award Information [Abstract]
Aggregate offering price of common stock	$ 6

EQUITY, SHARE-BASED COMPENSAT_5

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Share-Based Compensation by Type of Award (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan	$ 316	$ 312
Common Stock [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan	$ 100
Common Stock Issued under Equity Incentive Plans [Abstract]
Shares issued (in shares)	16,500	17,534	134,984	36,881
Grant date fair value (in dollars per share)	$ 1.16
Nonvested common stock outstanding (in shares)	0
Common Stock [Member] | Consultant [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan		$ 100
Common Stock Issued under Equity Incentive Plans [Abstract]
Shares issued (in shares)		17,534
Grant date fair value (in dollars per share)		$ 1.11
Common Stock [Member] | Vendor [Member]
Common Stock Issued under Equity Incentive Plans [Abstract]
Shares issued (in shares)	31,304
Grant date fair value (in dollars per share)	$ 1.14
Common Stock, Vested at Issuance and Nonvested at Issuance [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan	$ 95	$ 105
Stock Options [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan	99	85
Restricted Stock Units [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plan	$ 122	$ 122

EQUITY, SHARE-BASED COMPENSAT_6

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Stock Options (Details) - Stock Options [Member] - $ / shares	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Line Items]
Options exercisable period			4 years
Shares Under Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	1,523,840	996,009	996,009
Granted (in shares)		653,004
Forfeited (in shares)	(77,357)	(125,173)
Outstanding at end of period (in shares)	1,446,483	1,523,840	1,446,483	996,009
Options, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 2.24	$ 3.23	$ 3.23
Granted (in dollars per share)		1.22
Forfeited (in dollars per share)	4.28	4.74
Outstanding at end of period (in dollars per share)	$ 2.13	2.24	$ 2.13	$ 3.23
Options, Weighted Average Grant Date Fair Value [Abstract]
Granted (in dollars per share)		$ 0.73
Options, Weighted Average Remaining Contractual Life [Abstract]
Outstanding, weighted average remaining contractual life	8 years 7 months 6 days	8 years 9 months 18 days		8 years 1 month 6 days
Granted		10 years
Forfeited	7 years 2 months 12 days	7 years 2 months 12 days

EQUITY, SHARE-BASED COMPENSAT_7

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended				6 Months Ended		12 Months Ended
		Jun. 30, 2020		Mar. 31, 2020		Jun. 30, 2020		Dec. 31, 2019	Jun. 30, 2020
Weighted Average Remaining Vesting and Expense Period [Abstract]
Share-based compensation expense recognized		$ 316		$ 312
Restricted Stock Units [Member]
Weighted Average Remaining Vesting and Expense Period [Abstract]
Share-based compensation expense reversal on forfeited shares				100
Share-based compensation expense recognized		$ 122		$ 122
Restricted Stock Units [Member] | Minimum [Member]
Weighted Average Remaining Vesting and Expense Period [Abstract]
Award vesting period		1 year
Restricted Stock Units [Member] | Maximum [Member]
Weighted Average Remaining Vesting and Expense Period [Abstract]
Award vesting period		5 years
Restricted Stock Units [Member] | Employee and Director [Member]
Restricted Stock Award Activity, Number [Roll Forward]
Beginning balance, Nonvested (in shares)		348,062		1,148,062		1,148,062
Granted to director (in shares)	[1]	477,018
Cancelled (in shares)				(625,000)
Forfeited (in shares)		(30,000)		(175,000)	[2]
Vested (in shares)	[3]	(115,904)
Ending balance, Nonvested (in shares)		679,176	[4],[5]	348,062		679,176	[4],[5]	1,148,062
Unrecognized Stock Compensation [Abstract]
Unrecognized stock compensation		$ 113		$ 377		$ 377
Granted to director	[1]	426
Cancelled				0
Vested	[3]	0
Expensed		(122)		(122)	[6]
Forfeited		(24)		(142)	[2]
Unrecognized stock compensation		$ 393	[4],[5]	$ 113		$ 393	[4],[5]	$ 377
Weighted Average Remaining Vesting and Expense Period [Abstract]
Weighted average expense period (Years)		9 months 18 days	[4],[5]	1 year 2 months 12 days				1 year 4 months 24 days
Nonvested shares (in shares)		679,176	[4],[5]	348,062		679,176	[4],[5]	1,148,062	679,176	[4],[5]
Restricted Stock Units [Member] | Director [Member] | Maximum [Member]
Weighted Average Remaining Vesting and Expense Period [Abstract]
Award vesting period						1 year
Vesting June 2021 [Member] | Restricted Stock Units [Member]
Restricted Stock Award Activity, Number [Roll Forward]
Ending balance, Nonvested (in shares)		361,114				361,114
Weighted Average Remaining Vesting and Expense Period [Abstract]
Nonvested shares (in shares)		361,114				361,114			361,114
Vesting Price Equal to Volume Weighted Average Trading Price of Common Stock [Member] | Restricted Stock Units [Member]
Restricted Stock Award Activity, Number [Roll Forward]
Ending balance, Nonvested (in shares)		318,062				318,062
Weighted Average Remaining Vesting and Expense Period [Abstract]
Number of trading days						65 days
Nonvested shares (in shares)		318,062				318,062			318,062
Vesting Price Equals or Exceeds $5.00 [Member] | Restricted Stock Units [Member]
Restricted Stock Award Activity, Number [Roll Forward]
Ending balance, Nonvested (in shares)		31,806				31,806
Weighted Average Remaining Vesting and Expense Period [Abstract]
Nonvested shares (in shares)		31,806				31,806			31,806
Vesting price (in dollars per share)									$ 5
Vesting Price Equals or Exceeds $10.00 [Member] | Restricted Stock Units [Member]
Restricted Stock Award Activity, Number [Roll Forward]
Ending balance, Nonvested (in shares)		95,419				95,419
Weighted Average Remaining Vesting and Expense Period [Abstract]
Nonvested shares (in shares)		95,419				95,419			95,419
Vesting price (in dollars per share)									$ 10
Vesting Price Equals or Exceeds $15.00 [Member] | Restricted Stock Units [Member]
Restricted Stock Award Activity, Number [Roll Forward]
Ending balance, Nonvested (in shares)		190,837				190,837
Weighted Average Remaining Vesting and Expense Period [Abstract]
Nonvested shares (in shares)		190,837				190,837			190,837
Vesting price (in dollars per share)									$ 15
[1]	The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies.
[2]	In the three months ended March 31, 2020, we reversed $0.1 million of expense recognized prior to January 1, 2020 on forfeited RSU shares.
[3]	Represents shares of common stock subject to RSUs which were vested when granted.
[4]	A total of 318,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 31,806 shares on the date the vesting price equals or exceeds $5.00 per share (ii) 95,419 shares the date the vesting price equals or exceeds $10.00 per share and (iii) 190,837 shares the date the vesting price equals or exceeds $15.00 per share. Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence. The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.
[5]	RSUs for a total of 361,114 shares of common stock vest in June 2021, and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies
[6]	We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares.

EQUITY, SHARE-BASED COMPENSAT_8

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Warrants Activity (Details) - Warrants [Member] - $ / shares		3 Months Ended			12 Months Ended
		Jun. 30, 2020		Mar. 31, 2020	Dec. 31, 2019
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)		7,267,280		7,532,280
Cash exercised (in shares)		(12,948)
Cashless exercised (in shares)	[1]	(215,740)
Expired (in shares)		(392,676)		(265,000)
Outstanding at end of period (in shares)		6,645,916	[2]	7,267,280	7,532,280
Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)		$ 1.18		$ 1.32
Cash exercised (in dollars per share)		0.96
Cashless exercised (in dollars per share)		0.96
Expired (in dollars per share)		4.60		5.25
Outstanding at end of period (in dollars per share)		$ 0.98	[2]	$ 1.18	$ 1.32
Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life		1 year 8 months 12 days		1 year 8 months 12 days	1 year 10 months 24 days
Issuance of common stock upon cashless exercise of warrants (in shares)		54,629
Warrants under cashless exercise feature		7,267,280		7,267,280	7,532,280
Weighted average exercise price (in dollars per share)		$ 1.18		$ 1.18	$ 1.32
$0.96 [Member]
Shares Under Warrants [Roll Forward]
Outstanding at end of period (in shares)		3,484,675
Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at end of period (in dollars per share)		$ 0.96
Warrants, Additional Disclosures [Abstract]
Warrants under cashless exercise feature		3,484,675
Weighted average exercise price (in dollars per share)		$ 0.96
$5.25 [Member]
Shares Under Warrants [Roll Forward]
Outstanding at end of period (in shares)		25,000
Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at end of period (in dollars per share)		$ 5.25
Warrants, Additional Disclosures [Abstract]
Warrants under cashless exercise feature		25,000
Weighted average exercise price (in dollars per share)		$ 5.25
[1]	In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants.
[2]	Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. As of June 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an average exercise price of $5.25 per share. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature.

LOSS PER SHARE (EPS) (Details)

LOSS PER SHARE (EPS) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
NUMERATOR [Abstract]
Basic and diluted - loss from continuing operations	$ (3,949)	$ (3,659)	$ (6,982)	$ (6,670)
DENOMINATOR [Abstract]
Weighted average number of shares of shares of common stock outstanding (in shares)	40,041,888	33,204,332	40,002,522	31,382,927
Weighted average number of shares of common stock underlying vested restricted stock units (in shares)	10,275	0	5,138	0
Basic EPS - weighted average number of shares outstanding (in shares)	40,052,163	33,204,332	40,007,660	31,382,927
Effect of dilutive securities outstanding (in shares)	0	0	0	0
Diluted EPS - weighted average number of shares outstanding (in shares)	40,052,163	33,204,332	40,007,660	31,382,927

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENTS (Details) $ in Thousands	Jun. 30, 2020USD ($)
Derivative, Fair Value, Net [Abstract]
Fair value of open futures recorded in Accumulated OCI	$ (48)
Credit risk associated with open derivative financial instruments	0
Other Current Assets [Member]
Derivative, Fair Value, Net [Abstract]
Derivative receivable	$ 500

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) $ in Millions	Jun. 30, 2020USD ($)
Level 3 [Member]
Fair Value Measurements [Abstract]
Fair value of operating leases liabilities	$ 0.1

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Legal Matters [Abstract]
Cost of goods sold		$ 7,127	$ 6,463	$ 15,862	$ 12,484
Amount of liability		9,952		9,952		$ 8,749
Legal Matters [Member]
Legal Matters [Abstract]
Cost of goods sold		200
Amount of liability		$ 200		$ 200
Subsequent Event [Member] | Legal Matters [Member]
Legal Matters [Abstract]
Amount of contract dispute settlement	$ 200

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	3 Months Ended	6 Months Ended
	Mar. 31, 2019$ / sharesshares	Jun. 30, 2020Nominee$ / shares
Minimum [Member]
Related Party Transaction Information [Abstract]
Ownership percentage		19.99%
Ari Gendason [Member] | Continental Grain Company [Member]
Related Party Transaction Information [Abstract]
Ownership interest percentage		26.50%
Sale of common stock (in shares) | shares	666,667
Share price (in dollars per share)	$ 3
Exercise price per warrant (in dollars per share)		$ 0.01
Number of nominee for the Board of Directors related party can designate | Nominee		1
Ari Gendason [Member] | Continental Grain Company [Member] | Private Placement [Member]
Related Party Transaction Information [Abstract]
Shares callable by Prefunded Warrant (in shares) | shares	1,003,344
Share price (in dollars per share)	$ 2.99

TRANSACTIONS WITH EMPLOYEES (De

TRANSACTIONS WITH EMPLOYEES (Details) - Wayne Wilkison [Member] - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2019	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Employee Transaction [Abstract]
Amount paid to related parties	$ 1.4	$ 1.4
Amounts payable to entities			$ 0	$ 0

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details)	Aug. 11, 2020
Subsequent Event [Member] | Peter G. Bradley [Member] | Minimum [Member]
Subsequent Events [Abstract]
Number of years experience as an executive	23 years